-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 1, CDE issued a notice on soliciting opinions on the Catalogue of Reference Preparations of Chemical Generic Drugs (Fifty-sixth Batch) (Draft for Comment)
.
36 drugs including articaine epinephrine injection and rosuvastatin calcium tablets were not approved
The original text is as follows:
Notice on soliciting opinions on the "Catalogue of Chemical Generic Drug Reference Preparations (Fifty-sixth Batch)" (Draft for Comments)
Release date: 20220301
According to the "Announcement on the Selection and Determination of Reference Preparations for Chemical Generic Drugs" (No.
25, 2019) issued by the State Administration on March 28, 2019, our center organized the selection of the fifty-sixth batch of reference preparations (see Attachment), is now publicized for comments
.
During the announcement period, please provide feedback to the Center for Drug Evaluation through the "Application for Questionable Varieties of Reference Preparations" module under the reference preparation selection application platform.
In order to better serve the applicants, please provide sufficient basis and proof materials for feedback, and the feedback materials should be stamped.
The official seal of the unit, and provide your real name and contact information
.
Announcement period: March 1, 2022 to March 14, 2022 (10 working days)
.
Center for Drug Evaluation, State Drug Administration
March 1, 2022
Original attachment:
[1] "Catalogue of Reference Preparations of Chemical Generic Drugs (The Fifty-sixth Batch)" (Draft for Comment) (1)
[2] Application form for objection to chemical generic drug reference preparations
If this article violates your rights, please contact us